Expression and role of MHC class I-related chain in myeloma cells

Trinchieri, 1989, Biology of natural killer cells, Adv Immunol, 47, 187, 10.1016/S0065-2776(08)60664-1 Pende, 2001, Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin, Eur J Immunol, 31, 1076, 10.1002/1521-4141(200104)31:4<1076::AID-IMMU1076>3.0.CO;2-Y Groh, 1999, Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB, Proc Natl Acad Sci USA, 96, 6879, 10.1073/pnas.96.12.6879 Pende, 2002, Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity, Cancer Res, 62, 6178 Salih, 2003, Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia, Blood, 102, 1389, 10.1182/blood-2003-01-0019 Jinushi, 2003, Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid, Int J Cancer, 104, 354, 10.1002/ijc.10966 Vivier, 2002, Lymphocyte activation via NKG2D: towards a new paradigm in immune recognition?, Curr Opin Immunol, 14, 306, 10.1016/S0952-7915(02)00337-0 Bauer, 1999, Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA, Science, 285, 727, 10.1126/science.285.5428.727 Wu, 1999, An activating immunoreceptor complex formed by NKG2D and DAP10, Science, 285, 730, 10.1126/science.285.5428.730 Groh, 1996, Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium, Proc Natl Acad Sci USA, 93, 12445, 10.1073/pnas.93.22.12445 Groh, 2001, Costimulation of CD8 alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells, Nat Immunol, 2, 255, 10.1038/85321 Tieng, 2002, Binding of Escherichia coli adhesion AfaE to CD55 triggers cell-surface expression of the MHC class I-related molecule MICA, Proc Natl Acad Sci USA, 99, 2977, 10.1073/pnas.032668099 Das, 2001, MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function, Immunity, 15, 83, 10.1016/S1074-7613(01)00168-6 Cunningham, 1998, A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results, Br J Haematol, 102, 495, 10.1046/j.1365-2141.1998.00795.x Ludwig, 1995, Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies, Ann Oncol, 6, 467, 10.1093/oxfordjournals.annonc.a059217 2001, Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients, Br J Haematol, 113, 1020, 10.1046/j.1365-2141.2001.02857.x Singhal, 1999, Antitumor activity of thalidomide in refractory multiple myeloma, N Engl J Med, 341, 1565, 10.1056/NEJM199911183412102 Davies, 2001, Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma, Blood, 98, 210, 10.1182/blood.V98.1.210 Kunzmann, 2000, Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma, Blood, 96, 384, 10.1182/blood.V96.2.384 Das, 2001, Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates, Blood, 98, 1616, 10.1182/blood.V98.5.1616 Alyea, 2003, Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect, Bone Marrow Transplant, 32, 1145, 10.1038/sj.bmt.1704289 Barlogie, 2004, Treatment of multiple myeloma, Blood, 103, 20, 10.1182/blood-2003-04-1045 Lokhorst, 2004, The occurrence of graft versus host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma, Blood, 103, 4362, 10.1182/blood-2003-11-3862 Frohn, 2002, Anti-myeloma activity of natural killer lymphocytes, Br J Haematol, 119, 660, 10.1046/j.1365-2141.2002.03879.x Garcia-Sanz, 1996, Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications, Br J Haematol, 93, 81, 10.1046/j.1365-2141.1996.4651006.x Gonzalez, 1992, Increased expression of natural-killer-associated and activation antigens in multiple myeloma, Am J Hematol, 39, 84, 10.1002/ajh.2830390203 King, 1996, Natural killer cells and CD56+ T cells in the blood of multiple myeloma patients: analysis by 4-colour flow cytometry, Cytometry, 26, 121, 10.1002/(SICI)1097-0320(19960615)26:2<121::AID-CYTO4>3.0.CO;2-J Osterborg, 1990, Natural killer cell activity in monoclonal gammopathies: relation to disease activity, Eur J Haematol, 45, 153, 10.1111/j.1600-0609.1990.tb00443.x Bahram, 1994, A second lineage of mammalian major histocompatibility complex class I genes, Proc Natl Acad Sci USA, 91, 6259, 10.1073/pnas.91.14.6259 Farag, 2002, Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect, Blood, 100, 1935, 10.1182/blood-2002-02-0350 Cosman, 2001, ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor, Immunity, 14, 123, 10.1016/S1074-7613(01)00095-4 Takahashi, 2001, A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells, Leuk Res, 25, 77, 10.1016/S0145-2126(00)00087-4 Carbone, 2005, HLA class-I, NKG2D and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells, Blood, 105, 251, 10.1182/blood-2004-04-1422